Drugs / SILTARTOXATUG
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06607380 | Aug 2022 → Apr 2023 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05842798 | Oct 2021 → Feb 2022 | — | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04629131 | Nov 2020 → Aug 2021 | — | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05625477 | Apr → May 2022 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05664750 | Dec 2022 → Mar 2023 | tetanus | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SILTARTOXATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068174 ↗ |
| Known as | TNM002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607380 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody against tetanus toxin” NCT04629131 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT04629131 ↗ |